ADMA Biologics, an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, has received approval from the FDA for the company’s expanded manufacturing process, enabling fractionation and purification of a 4,400-liter plasma pool for the manufacture of Intravenous Immune Globulin (IVIG).   “The FDA approval of the 4,400-liter IVIG plasma pool production scale process is a transformative milestone for the ADMA organiz...